Research
Hormonal
The phenotype of 'metabolically healthy obesity' (MHO) is a transient state that progresses over time to an unhealthy phenotype, particularly in children and adolescents, and is associated with increased cardiovascular risk compared to metabolically healthy normal weight individuals.
Even if your blood pressure and cholesterol are normal, having obesity is not 'healthy' in the long term. It is a temporary state that often leads to metabolic problems like diabetes and heart disease, especially as you age. You should still focus on maintaining a healthy weight and physical fitness to prevent this progression.
GoodRefutesHIGH confidence
The phenotype of 'medically healthy obesity' appears to be a transient state that progresses over time to an unhealthy phenotype, especially in children and adolescents.
Why this rating
Based on longitudinal studies cited in the scientific statement.
Source
The Science of Obesity Management: An Endocrine Society Scientific Statement
George A. Bray et al. · Endocrine Reviews · 2018
DOI 10.1210/er.2017-00253
narrative_reviewCited 806×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Weight loss achieved through reduced energy intake and increased energy expenditure reduces the risk and severity of obesity-associated diseases (including type 2 diabetes, cardiovascular disease, and cancer) in a dose-related manner, where greater weight loss yields better health outcomes.Strong
- Obesity is a stigmatized condition where the desire for cosmetic weight loss often exceeds the desire for health benefits, leading to a mismatch between patient expectations and clinical outcomes, which negatively affects treatment adherence and drug regulation.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →